RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant

Clinical Cancer Research

Volumn 16, Issue 8, 2010, Pages 2246-2256

  Ricci, Clara ^a   Fermo, Elisa ^b   Corti, Stefania ^c   Molteni, Mauro ^e   Faricciotti, Alessio ^d   Cortelezzi, Agostino ^a   Deliliers, Giorgio Lambertenghi ^a   Beran, Miloslav ^f   Onida, Francesco ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Unità Operativa Ematologia 2   (Italy)

^c MAGGIORE HOSPITAL   (Italy)

^d Ospedale di Circolo di Melegnano   (Italy)

^e DESIO HOSPITAL   (Italy)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; RAS PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER EPIDEMIOLOGY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MALE; MYELODYSPLASTIC CHRONIC MYELOMONOCYTIC LEUKEMIA; MYELOPROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS;

EID: 77950980368     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2112     Document Type: Article

References (45)

1. Onida F, Beran M. Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep 2004;3:218-226
2. Bowen DT. Chronic myelomonocytic leukemia: lost in classification? Hematol Oncol 2005;23:26-33.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199
4. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994;87:746-754 (Pubitemid 24264647)
5. Nosslinger T, Reisner R, Gruner H, et al. Dysplastic versus proliferative CMML - a retrospective analysis of 91 patients from a single institution. Leuk Res 2001;25:741-747 (Pubitemid 32727976)
6. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002;99:840-849 (Pubitemid 34525544)
7. Beran M, Wen S, Shen Y, et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma 2007;48:1150-1160
8. Voglova J, Chrobak L, Neuwirtova R, Malaskova V, Straka L. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia - distinct subgroups or two stages of the same disease? Leuk Res 2001;25:493-499
9. Gonzalez-Medina I, Bueno J, Torrequebrada A, Lopez A, Vallespi T, Massague I. Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res 2002;26:821-824
10. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML - dysplastic versus proliferative type. Leuk Res 1998;22:871-878 (Pubitemid 28438295)
11. Wang SA, Galili N, Cerny J, et al. Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. Am J Clin Pathol 2006;126:789-797 (Pubitemid 44707630)
12. Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 2008;22:1308-1319
13. Emanuel PD. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 2008;22:1335-1342
14. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer 2008;8:299.
15. Beran M. Chronic myelomonocytic leukemia. In: Ansell SM, editor. Rare hematological malignancies. New York (NY): Springer; 2008,p. 107-132
16. Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood 2006;108:2349-2357 (Pubitemid 44497519)
17. Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. Cancer Res 2007;67:7139-7146 (Pubitemid 47206541)
18. Braun BS, Shannon K. Targeting Ras in myeloid leukemias. Clin Cancer Res 2008;14:2249-2252
19. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-2301
20. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009;23:900-904
21. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23:1343-1345
22. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114:144-147
23. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009;113:6403-6410
24. Couronne L, Lippert E, Andrieux J, et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 2009.
25. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838-842
26. Kosmider O, Gelsi-Boyer V, Ciudad M, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009.
27. Mullighan CG. TET2 mutations in myelodysplasia and myeloid malignancies. Nat Genet 2009;41:766-767
28. Lee BH, Tothova Z, Levine RL, et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 2007;12:367-380 (Pubitemid 47554548)
29. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370-3373
30. Pich A, Riera L, Sismondi F, et al. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol 2009;62:798-801.
31. Zinkel SS, Ong CC, Ferguson DO, et al. Proapoptotic BID is required for myeloid homeostasis and tumor suppression. Genes Dev 2003;17:229-239
32. Emanuel PD. Mixed myeloproliferative and myelodysplastic disorders. Curr Hematol Malig Rep 2007;2:9-12.
33. Tyner JW, Erickson H, Deininger MW, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood 2009;113:1749-1755
34. Niv H, Gutman O, Henis YI, Kloog Y. Membrane interactions of a constitutively active GFP-Ki-Ras 4B and their role in signaling. Evidence from lateral mobility studies. J Biol Chem 1999;274:1606-1613 (Pubitemid 129507753)
35. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007;13:4954-4955
36. Archambeault S, Flores NJ, Yoshimi A, et al. Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood 2008;111:1124-1127 (Pubitemid 351213391)
37. Zhang J, Wang J, Liu Y, et al. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood 2009;113:1304-1314
38. Sabnis AJ, Cheung LS, Dail M, et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 2009;7:e59.
39. Small D. Targeting FLT3 for the treatment of leukemia. Semin Hematol 2008;45:S17-21.
40. Sayyah J, Sayeski PP. Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies. Curr Oncol Rep 2009;11:117-124
41. Tyner JW, Loriaux MM, Erickson H, et al. High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia. Leukemia 2009;23:406-409
42. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 1997;272:14093-14097
43. Feldman EJ, Cortes J, DeAngelo DJ, et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia 2008;22:1707-1711
44. Chow LQ, Eckhardt SG, O'Bryant CL, et al. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2008;62:631-646
45. Ganguly AK, Doll RJ, Girijavallabhan VM. Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. The discovery and development of SCH 66336. Curr Med Chem 2001;8:1419-1436